Price
$31.21
Increased by +1.93%
Dollar volume (20D)
52.04 M
ADR%
3.31
Earnings report date
Jul 22, 2025
Shares float
162.28 M
Shares short
12.76 M [7.87%]
Shares outstanding
164.90 M
Market cap
5.05 B
Beta
0.47
Price/earnings
14.58
20D range
26.70 31.99
50D range
25.56 35.58
200D range
25.56 36.45

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.

It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.

Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder.

The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products.

It has collaboration agreements primarily with Janssen PharmaceuticaN. V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International.

Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Apr 29, 25 0.29
Decreased by -32.33%
0.24
Increased by +18.87%
Feb 12, 25 1.05
Increased by +377.27%
0.76
Increased by +37.61%
Oct 24, 24 0.72
Increased by +12.50%
0.74
Decreased by -2.70%
Jul 24, 24 0.70
Increased by +27.27%
0.70
May 1, 24 0.43
Increased by +4.20 K%
0.58
Decreased by -25.86%
Feb 15, 24 0.22
Increased by +57.14%
0.51
Decreased by -56.86%
Oct 25, 23 0.64
Increased by +3.10 K%
0.44
Increased by +45.45%
Jul 26, 23 0.55
Increased by +816.67%
0.46
Increased by +19.57%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 25 306.51 M
Decreased by -12.52%
22.46 M
Decreased by -39.00%
Increased by +7.33%
Decreased by -30.27%
Dec 31, 24 429.99 M
Increased by +13.91%
146.50 M
Increased by +29.90%
Increased by +34.07%
Increased by +14.04%
Sep 30, 24 378.14 M
Decreased by -0.73%
92.38 M
Increased by +93.44%
Increased by +24.43%
Increased by +94.87%
Jun 30, 24 399.13 M
Decreased by -35.35%
91.36 M
Decreased by -61.46%
Increased by +22.89%
Decreased by -40.39%
Mar 31, 24 350.37 M
Increased by +21.83%
36.83 M
Increased by +188.01%
Increased by +10.51%
Increased by +172.24%
Dec 31, 23 377.48 M
Increased by +23.89%
112.78 M
Increased by +499.16%
Increased by +29.88%
Increased by +422.18%
Sep 30, 23 380.94 M
Increased by +50.95%
47.76 M
Increased by +174.65%
Increased by +12.54%
Increased by +149.45%
Jun 30, 23 617.40 M
Increased by +123.52%
237.06 M
Increased by +886.65%
Increased by +38.40%
Increased by +451.94%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY